Note: Ingredients listed on restricted chemical lists
EC/CAS
8001-54-5
Name of the chemical
Benzalkonium chloride; Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
Concentration
N/A
EC/CAS
77-92-9
Name of the chemical
Citric acid
Concentration
N/A
EC/CAS
54-64-8
Name of the chemical
Sodium o-(ethylmercurithio)benzoate
Concentration
N/A
EC/CAS
1310-73-2
Name of the chemical
sodium hydroxide
Concentration
N/A
EC/CAS
7647-01-0
Name of the chemical
Hydrochloric acid
Concentration
N/A
General Information
Product name
Brimonidine Tartrate Ophthalmic Solution 0.2%
Icons in SDS
Company Information
company name
Wintac Limited
Section 2
SECTION 2: Hazards identification
EMERGENCY OVERVIEW Appearance Clear, greenish yellow solution, free from visible particles. Eye: Brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The preservative in Brimonidine tartrate ophthalmic solution 0.2%, benzalkonium chloride, may be absorbed by soft contact lenses. Patients wearing soft contact lenses should be instructed to wait at least 15 minutes after instilling Brimonidine tartrate ophthalmic solution 0.2% to insert soft contact lenses. Skin: Irritant Ingestion: Harmful if swallowed Inhalation: Harmful if inhaled
Potential chronic health
Not known Target Organs: Liver
Medical Conditions Generally Aggravated by Exposure
No information is available on over dosage in humans. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.
